Anterogen.Co.,Ltd.

KOSDAQ 065660.KQ

Anterogen.Co.,Ltd. Operating Income for the year ending December 31, 2023: USD -3.90 M

Anterogen.Co.,Ltd. Operating Income is USD -3.90 M for the year ending December 31, 2023, a -6.12% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Anterogen.Co.,Ltd. Operating Income for the year ending December 31, 2022 was USD -3.67 M, a -67.19% change year over year.
  • Anterogen.Co.,Ltd. Operating Income for the year ending December 31, 2021 was USD -2.20 M, a 35.57% change year over year.
  • Anterogen.Co.,Ltd. Operating Income for the year ending December 31, 2020 was USD -3.41 M, a -36.01% change year over year.
  • Anterogen.Co.,Ltd. Operating Income for the year ending December 31, 2019 was USD -2.51 M, a -14.76% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
SV Wall Street
KOSDAQ: 065660.KQ

Anterogen.Co.,Ltd.

CEO Seong-Gu Lee
IPO Date Feb. 15, 2016
Location South Korea
Headquarters Namsung Plaza
Employees 35
Sector Healthcare
Industries
Description

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

Similar companies

005880.KS

Korea Line Corporation

USD 1.12

-2.45%

006340.KS

Daewon Cable. Co., Ltd.

USD 2.27

-7.25%

001440.KS

Taihan Electric Wire Co., Ltd.

USD 8.61

-3.50%

008350.KS

Namsun Aluminum Co., Ltd.

USD 0.95

-3.80%

StockViz Staff

February 5, 2025

Any question? Send us an email